Welcome
Support Centre
24 October 2014 
ISRCTN Register - International Standard Randomized Controlled Trial Number
Trial registration
Unique identification scheme
International databases
home  |   my details  |   ISRCTN Register  |   mRCT  |   links  |   information  |   news
Find trials
ISRCTN Register
tips on searching

Registration
New application
Updating record

Information
introduction
governing board
ISRCTN FAQs
data set
letter of agreement
request information
guidance notes
statistics

[ Print-friendly version ]
Deep brain stimulation (DBS) of the nucleus accumbens in treatment-refractory patients with obsessive-compulsive disorder (OCD)
ISRCTN ISRCTN23255677
DOI 10.1186/ISRCTN23255677
ClinicalTrials.gov identifier
EudraCT number
Public title Deep brain stimulation (DBS) of the nucleus accumbens in treatment-refractory patients with obsessive-compulsive disorder (OCD)
Scientific title
Acronym N/A
Serial number at source N/A
Study hypothesis DBS in the nucleus accumbens can lead to long-term improvement of obsessive-compulsive symptoms and functioning, without unacceptable side-effects.
Lay summary Not provided at time of registration
Ethics approval Not provided at time of registration
Study design Randomized, placebo-controlled trial
Countries of recruitment Netherlands
Disease/condition/study domain Obsessive-compulsive disorder (OCD)
Participants - inclusion criteria 1. Primary diagnosis: OCD (300.3) according to Diagnostic and Statistical Manual of Mental Disorders - Fourth Edition (DSM-IV) criteria using the mini-international neuropsychiatric interview (MINI) plus interview as a diagnostic instrument
2. Illness duration >5 years
3. Yale-Brown obsessive-compulsive scale (Y-BOCS) total >27, measured twice at least two weeks apart
4. Disabling severity with substantial functional impairment according to the DSM-IV criterion C and a global assessment of function (GAF) score of <45
5. Age 18 - 65 years
6. Written informed consent
7. Able to fully understand the consequences of the procedure (intelligence quotient [IQ] >80)
8. Dutch speaking and able to answer all study questions
9. Capable to make his or her own choice without coercion
10. Treatment refractory is defined as no response or insufficient response (still fulfilling the inclusion criteria) following:
a. Two treatments with a selective serotonin reuptake inhibitor (SSRI) at a maximum dose for and least 12 weeks
b. One treatment with clomipramine at the maximum dose for at least 12 weeks, with assessment of clomipramine/desmethylclomipramine plasma levels to control for sufficient bioavailability
c. At least one augmentation trial with an a typical antipsychotic for 8 weeks in combination with an SSRI
d. At least one (cognitive) behavioural therapy trial for 16 weeks in combination with an effective drug for the treatment of OCD
Participants - exclusion criteria Any of the following unstable physical conditions: Parkinson's disease, dementia, epilepsy, schizophrenia or history of psychosis, alcohol or substance abuse during last 6 months, current tic disorder, antisocial personality disorder, body dismorphic disorder, pregnancy, use of psychiatric medication other than stable use of one SSRI or clomipramine, one benzodiazepine, one atypical antipsychotic.
Anticipated start date 27/03/2006
Anticipated end date 01/07/2007
Status of trial Completed
Patient information material
Target number of participants 16
Interventions Stereotactic implantation of bilateral DBS electrodes in the nucleus accumbens.
Placebo: no stimulation.
Primary outcome measure(s) 1. Change on the Y-BOCS
2. Number of responders, defined as a decrease on the Y-BOCS >35%
Secondary outcome measure(s) 1. Hamilton Depression Rating Scale (HDRS-17)
2. Hamilton Anxiety Scale (HAS)
3. Symptom Checklist 90 (SCL-90)
4. Quality of life enjoyment and satisfaction questionnaire
5. Sheehan Disability Scale (SDS)
6. Clinical Global Impression (CGI)
7. Y-BOCS checklist
Sources of funding Academic Medical Center (AMC)
Trial website
Publications 1. 2010 results in: http://www.ncbi.nlm.nih.gov/pubmed/20921122
2. 2013 results in http://www.ncbi.nlm.nih.gov/pubmed/23715912
Contact name Dr  P.R.  Schuurman
  Address Academic Medical Center (AMC)

Department of Neurosurgery

P.O. Box 22660
  City/town Amsterdam
  Zip/Postcode 1100 DD
  Country Netherlands
  Tel +31 (0)20 5669111
  Email p.r.schuurman@amc.nl
Sponsor Academic Medical Center (AMC) (The Netherlands)
  Address P.O. Box 22660
  City/town Amsterdam
  Zip/Postcode 1100 DD
  Country Netherlands
Date applied 07/06/2006
Last edited 30/05/2013
Date ISRCTN assigned 07/06/2006
Submit your trial protocol
Submit to Trials journal
Follow us on Twitter
© 2014 ISRCTN unless otherwise stated.